Medicare Will Pick Drugs For Negotiation Based On Gross Sales, Disadvantaging Highly-Rebated Products
But on the bright side, knowing that eligibility will not be based on net sales to Medicare makes it easier to predict which drugs will be selected first.
You may also be interested in...
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
Medicare Price Negotiation: Sponsors Will Have A Say, But Likely Not Sway As Timetable Comes Into Focus
CMS details when it will release information and receive public comments in the lead-up to publishing the initial list of drugs to be negotiated this fall.
Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.